[Featured Stock] Hyundai Pharm Soars on New Drug Launch News
[Asia Economy Reporter Junho Hwang] Hyundai Pharm is showing strong performance in the stock market on the 1st following the official launch of 'Hypegilsan' (active ingredient: Donepezil Hydrochloride), the first domestic tablet formulation Alzheimer's-type dementia treatment drug.
At 1:37 PM that day, Hyundai Pharm was trading at 5,770 KRW, up 1,215 KRW (26.67%) compared to the previous trading day.
Hypegilsan received product approval from the Ministry of Food and Drug Safety in April as a dementia treatment drug that can be taken by patients at all stages, from mild to severe dementia. The dosages are composed of two types: 5mg and 10mg.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Hyundai Pharm official stated, "In the case of dementia symptom treatments, steady seller products and formulations dominate the market, so it is not easy for new products to gain attention. Products that enhance convenience through formulation differentiation find it much easier to create new markets or target niche markets, so Hypegilsan, which was launched this time, is also a product with high expectations."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.